NDA 217439 · Pfizer
Talzenna
Talazoparib Tosylate · Oral
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2024
Mar 7, 2024
Approved uses
3
Original approval plus efficacy supplements
Registered trials
108
5 Phase 3, 25 recruiting
FAERS reports
1,853
1,494 serious, 342 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Oct 28, 2026.
TALZENNA is a poly (ADP-ribose) polymerase (PARP) inhibitor indicated for: Breast Cancer • As a single agent, for the treatment of adult patients with deleterious or suspected deleterious germline BRCA -mutated (g BRCA m) HER2-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA‑authorized companion diagnostic for TALZENNA. ( 1.1 , 2.1 ) Prostate Cancer In combination with enzalutamide for the treatment of adult patients with: • metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test. ( 1.2 , 2.1 ) • metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene mutations, as detected by an FDA-authorized test. ( 1.2 , 2.1 ) 1.1 BRCA -mutated (g BRCA m) HER2-negative Locally Advanced or Metastatic Breast Cancer TALZENNA is indicated as a single agent for the treatment of adult patients with deleterious or suspected deleterious germline breast cancer susceptibility gene ( BRCA )-mutated (g BRCA m) human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer. Select patients for therapy based on an FDA-authorized companion diagnostic for TALZENNA [see Dosage and Administration (2.1) ] . 1.2 HRR Gene-Mutated Metastatic Prostate Cancer TALZENNA is indicated in combination with enzalutamide for the treatment of adult patients with: • metastatic androgen pathway modulation-resistant (mAPMR) prostate cancer with homologous recombination repair (HRR) gene mutations, as detected by an FDA-authorized test [see Dosage and Administration (2.1) ] . • metastatic androgen pathway modulation-naïve or -sensitive (mAPMN/S) prostate cancer with HRR gene...
Mechanism: Talazoparib is an inhibitor of PARP enzymes, including PARP1 and PARP2, which play a role in DNA repair. In vitro studies with cancer cell lines that harbored defects in DNA repair genes, including BRCA1 and BRCA2 , have shown that talazoparib-induced cytotoxicity may involve inhibition of PARP enzymatic activity and increased formation of PARP-DNA complexes resulting in DNA damage, decreased cell proliferation, and apoptosis. Talazoparib anti-tumor activity was observed in patient-derived xenograft breast cancer models bearing mutated BRCA1 or mutated BRCA2 or wild type BRCA1 and BRCA2 .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 26, 2026 Supplement 4 · Efficacy · priority review LabelLetter
- Jun 12, 2025 Supplement 3 · Efficacy · priority review LabelLetter
- Mar 7, 2024 Original approval · Type 5 - New Formulation or New Manufacturer LetterLabelReview
6 products under this application
- TALZENNA · TALAZOPARIB TOSYLATE EQ 0.75MG BASE · CAPSULE, ORAL · Prescription
- TALZENNA · TALAZOPARIB TOSYLATE EQ 0.35MG BASE · CAPSULE, ORAL · Prescription
- TALZENNA · TALAZOPARIB TOSYLATE EQ 0.1MG BASE · CAPSULE, ORAL · Prescription
- TALZENNA · TALAZOPARIB TOSYLATE EQ 1MG BASE · CAPSULE, ORAL · Prescription
- TALZENNA · TALAZOPARIB TOSYLATE EQ 0.5MG BASE · CAPSULE, ORAL · Prescription
- TALZENNA · TALAZOPARIB TOSYLATE EQ 0.25MG BASE · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Talazoparib" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
American Society of Clinical OncologyAcademic, hospital or other
NCT02693535 · 4,200 participants (planned) · Start Mar 14, 2016 · Primary completion Dec 31, 2027
Drug: Sunitinib (CLOSED TO ENROLLMENT); Trastuzumab and Pertuzumab (CLOSED TO ENROLLMENT) and 10 more · For: Lymphoma, Non-Hodgkin; Multiple Myeloma; Advanced Solid Tumors
Sites: Birmingham, Alabama; Phoenix, Arizona; Auburn, California · 181 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- Talazoparib + Enzalutamide vs. Enzalutamide Monotherapy in mCRPCPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT03395197 · 1,054 participants · Start Dec 18, 2017 · Primary completion Oct 3, 2022
Drug: Talazoparib with enzalutamide; Placebo with enzalutamide · For: mCRPC
Sites: Anchorage, Alaska; Chandler, Arizona; Gilbert, Arizona · 370 sites in all
The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolAcademic, hospital or other
NCT05406999 · 900 participants (planned) · Start Feb 1, 2020 · Primary completion Dec 31, 2026
Drug: ADT; Abiraterone Acetate and 6 more · For: Neoadjuvant Therapy; High Risk Prostate Cancer; Locally Advanced Prostate Cancer and 1 more
Sites: Nanjing, China
- Study of Talazoparib With Enzalutamide in Men With DDR Gene Mutated mCSPCPivotal-lookingActive, not recruiting
PfizerPfizer (PFE)
NCT04821622 · 599 participants · Start May 12, 2021 · Primary completion Feb 18, 2026
Drug: talazoparib plus enzalutamide; Placebo plus enzalutamide · For: Prostate Cancer
Sites: Birmingham, Alabama; Tucson, Arizona; Beverly Hills, California · 312 sites in all
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study)Pivotal-lookingCompleted
PfizerPfizer (PFE)
NCT01945775 · 431 participants · Start Oct 14, 2013 · Primary completion Sep 15, 2017
Drug: talazoparib; Physician's-Choice · For: Breast Neoplasms; BRCA 1 Gene Mutation; BRCA 2 Gene Mutation
Sites: Flagstaff, Arizona; Scottsdale, Arizona; Antioch, California · 362 sites in all
- The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and ImmunotherapyPivotal-lookingStatus unknown
Fondazione per la Medicina PersonalizzataAcademic, hospital or other
NCT04591431 · 400 participants · Start Oct 7, 2020 · Primary completion Dec 2024
Drug: Erlotinib; Trastuzumab and 24 more · For: Breast Cancer; Gastrointestinal Cancer; Non Small Cell Lung Cancer and 1 more
Sites: Ancona, Italy; Aviano, Italy; Bari, Italy · 37 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- anaemia285
- death194
- neoplasm progression171
- fatigue137
- off label use101
- thrombocytopenia100
- haemoglobin decreased85
- malignant neoplasm progression80
- platelet count decreased79
- febrile neutropenia71
- pancytopenia71
- nausea67
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2015 | 5 |
| 2016 | 2 |
| 2017 | 21 |
| 2018 | 29 |
| 2019 | 210 |
| 2020 | 202 |
| 2021 | 154 |
| 2022 | 199 |
| 2023 | 252 |
| 2024 | 239 |
| 2025 | 336 |
| 2026 | 204 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Talzenna (Talazoparib Tosylate)
2024 spending
$59.8M
Beneficiaries
790
3,741 claims
Per beneficiary
$75,749
$520.34 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,270,787 |
| 2021 | $7,758,691 |
| 2022 | $6,401,237 |
| 2023 | $14,816,664 |
| 2024 | $59,841,806 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial.
Agarwal N, Azad AA, Carles J, et al. · Lancet 2023 · Randomized Controlled Trial, Clinical Trial, Phase III
- Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation.
Litton JK, Rugo HS, Ettl J, et al. · N Engl J Med 2018 · Clinical Trial, Phase III, Multicenter Study
- PARP and Androgen-Signaling Inhibition plus ADT in Metastatic Prostate Cancer.
Agarwal N, Matsubara N, Azad AA, et al. · N Engl J Med 2026 · Randomized Controlled Trial, Multicenter Study
- Talazoparib plus enzalutamide in men with metastatic castration-resistant prostate cancer: final overall survival results from the randomised, placebo-controlled, phase 3 TALAPRO-2 trial.
Agarwal N, Azad AA, Carles J, et al. · Lancet 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Systemic Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer: ASCO Guideline Update.
Garje R, Riaz IB, Naqvi SAA, et al. · J Clin Oncol 2025 · Practice Guideline, Systematic Review
- First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial.
Fizazi K, Azad AA, Matsubara N, et al. · Nat Med 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Pfizer
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.